As a result, the suppression of AR in CAFs may potentially exacerbate the epithelial-mesenchymal transition and metastasis of prostate cancer, underpinning the association of AR loss in CAFs with adverse clinical outcomes in prostate cancer progression. Here, AR is linked to prostate carcinoma.